Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Consistent use of continuous glucose monitors (CGM) has the potential to improve glycemic control and related type 1 diabetes (T1D) health outcomes, however young adolescents with T1D are the least likely age group to begin and sustain use of CGM. The proposed study will conduct a feasibility trial of a behavioral intervention designed to optimize use of CGM in adolescents specifically targeting underrepresented populations in diabetes technology research.
Young adolescents (ages 10-15) with type 1 diabetes (T1D) are at high risk for deterioration of glycemic control and relatedly poor overall T1D self-management. Continuous glucose monitors (CGM) provide real-time indicators of glucose levels and alert users to hypoglycemia and hyperglycemia. Consistent, informed use of CGM has the potential to improve glycemic control and related T1D health outcomes. However, adolescents with T1D are the least likely age group to utilize CGM and significant health disparities exist in access to and use of CGM among youth from racial and ethnic minority backgrounds and youth with public insurance. Adolescent CGM users also continue to evidence A1c levels above recommended targets, potentially due challenges related to perceived CGM burden and related family functioning. Novel, developmentally targeted interventions delivered early in adolescence could promote optimal uptake and use of CGM and reduce psychosocial barriers to sustained use but must be evaluated in rigorous pilot trials that attend to health disparities. The current study proposes to evaluate an innovative behavioral intervention that utilizes certified diabetes care and education specialists (CDCES) to teach problem-solving and communication skills around CGM data and use, targeting adolescent-parent T1D interactions related to glucose data, individualized CGM challenges, and weekly adolescent-parent joint review of CGM reports. The intervention also addresses HCP knowledge of health disparities in diabetes technology through interactive education, and boosts family support through connection with peer parent consultants. This study aims to evaluate the preliminary efficacy of the behavioral intervention to enhance CGM use and resulting T1D health outcomes. Sixty adolescents and their parents will be recruited for this pilot randomized trial, randomly assigned to either an immediate intervention group or a delayed intervention group serving as a standard care comparison. Intervention content will be delivered via 3 telemedicine sessions with adolescents and a parent and supported by connection with a peer parent consultant. Medical and psychosocial data (including A1c, CGM indicators, CGM burdens and benefits, diabetes distress, and diabetes-related family conflict) will be collected from adolescents and a parent at baseline and three follow-up time points across the first year after CGM initiation. The investigators will employ quantitative and qualitative analyses to evaluate intervention feasibility, acceptability, and impact. Enhancing CGM access and use at this key developmental juncture provides an excellent opportunity for tailored support and problem-solving, resulting in potentially lasting improvement in diabetes self-management. Results of this pilot trial will directly inform a multi-site randomized clinical trial to evaluate efficacy, with the long term goal of identifying effective behavioral strategies that can be integrated into routine diabetes education and care.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Immediate intervention | Experimental | Participants randomized to the immediate intervention group will participate in 3 video-conferencing sessions with a Certified Diabetes Care and Education Specialist (CDCES) interventionist and connect with a peer parent consultant immediately post randomization (expected intervention duration: 3 months). |
|
| Wait-list/delayed intervention | Active Comparator | Participants randomized to the delayed intervention group will receive no intervention for 6 months post-randomization; after the 6-month follow-up period, the delayed intervention group also will participate in 3 video conferencing sessions with a CDCES interventionist and connect with a peer parent consultant (expected intervention duration: 3 months). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| diabetes education and parent coaching support | Behavioral | Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team. |
| Measure | Description | Time Frame |
|---|---|---|
| Glycemic control | hemoglobin A1c (HbA1c) | Baseline |
| Glycemic control | hemoglobin A1c (HbA1c) | 3 months post randomization |
| Glycemic control | hemoglobin A1c (HbA1c) | 6 months post randomization |
| Glycemic control | hemoglobin A1c (HbA1c) | 12 months post randomization |
| glycemic variability | Using 14-30 days of CGM data | Baseline |
| glycemic variability | Using 14-30 days of CGM data | 3 months post randomization |
| glycemic variability | Using 14-30 days of CGM data | 6 months post randomization |
| glycemic variability | Using 14-30 days of CGM data | 12 months post randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Family Conflict | The Diabetes Family Conflict Scale-Revised Scored 19-57 where a higher score indicates higher family conflict | Baseline |
| Family Conflict | The Diabetes Family Conflict Scale-Revised Scored 19-57 where a higher score indicates higher family conflict |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Randi Streisand, PhD | Children's National Hosptial | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children's National Research Institute | Washington D.C. | District of Columbia | 20010 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Apr 8, 2026 | |
| Reset | Apr 28, 2026 | |
| Release | May 5, 2026 | |
| Reset | May 29, 2026 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Apr 8, 2026 | Apr 28, 2026 | |||
| May 5, 2026 |
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
wait-list control; all participants receive intervention- randomized to start immediately or 6 months after CGM start
Not provided
Not provided
a research assistant blind to condition of participant will complete outcome assessments.
| 3 months post randomization |
| Family Conflict | The Diabetes Family Conflict Scale-Revised Scored 19-57 where a higher score indicates higher family conflict | 6 months post randomization |
| Family Conflict | The Diabetes Family Conflict Scale-Revised Scored 19-57 where a higher score indicates higher family conflict | 12 months post randomization |
| Diabetes Distress | Problem Areas in Diabetes scales (PAID) Scored 14-84 where higher scores indicate higher distress | Baseline |
| Diabetes Distress | Problem Areas in Diabetes scales (PAID) Scored 14-84 where higher scores indicate higher distress | 3 months post randomization |
| Diabetes Distress | Problem Areas in Diabetes scales (PAID) Scored 14-84 where higher scores indicate higher distress | 6 months post randomization |
| Diabetes Distress | Problem Areas in Diabetes scales (PAID) Scored 14-84 where higher scores indicate higher distress | 12 months post randomization |
| CGM benefits and burdens | Continuous glucose monitoring (CGM) Burdens and Benefits as assessed by The BenCGM and BurCGM | Baseline |
| CGM benefits and burdens | Continuous glucose monitoring (CGM) Burdens and Benefits as assessed by The BenCGM and BurCGM | 3 months post randomization |
| CGM benefits and burdens | Continuous glucose monitoring (CGM) Burdens and Benefits as assessed by The BenCGM and BurCGM | 6 months post randomization |
| CGM benefits and burdens | Continuous glucose monitoring (CGM) Burdens and Benefits as assessed by The BenCGM and BurCGM | 12 month post randomization |
| CGM use | Indicators of CGM use, including mean days work per week, will be evaluated to measure sustained use of CGM. | Baseline |
| CGM use | Indicators of CGM use, including mean days work per week, will be evaluated to measure sustained use of CGM. | 3 months post randomization |
| CGM use | Indicators of CGM use, including mean days work per week, will be evaluated to measure sustained use of CGM. | 6 months post randomization |
| CGM use | Indicators of CGM use, including mean days work per week, will be evaluated to measure sustained use of CGM. | 12 months post randomization |
| Diabetes self-management | The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month. Scored 0-100 with higher scores indicating higher adherence to diabetes management | Baseline |
| Diabetes self-management | The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month. Scored 0-100 with higher scores indicating higher adherence to diabetes management | 3 months post randomization |
| Diabetes self-management | The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month. Scored 0-100 with higher scores indicating higher adherence to diabetes management | 6 months post randomization |
| Diabetes self-management | The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month. Scored 0-100 with higher scores indicating higher adherence to diabetes management | 12 months post randomization |
| May 29, 2026 |
| Jun 18, 2026 |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |